Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CCR5 | P51681 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5901392 | 0.98 | TP53 (0.43) | TP53NPSR1TSHRSMN1; SMN2CCR5 | |
| SCHEMBL2164158 | 0.83 | TP53 (0.44) | TP53NPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL6981711 | 0.81 | KDM4E (0.41) | TP53TSHRSMN1; SMN2CCR5MAPT | |
| SCHEMBL27510349 | 0.80 | CA1 (0.42) | CCR5 | |
| SCHEMBL13432205 | 0.77 | TP53 (0.47) | TP53NPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL22171142 | 0.76 | ALDH1A1 (0.53) | TP53NPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL14317700 | 0.75 | CHRNB2 (0.46) | TSHRCCR5 | |
| SCHEMBL429660 | 0.75 | TP53 (0.48) | TP53NPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL1773952 | 0.74 | TP53 (0.52) | TP53NPSR1TSHRSMN1; SMN2MAPT | |
| SCHEMBL6955528 | 0.72 | ALDH1A1 (0.50) | TP53TSHRSMN1; SMN2MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-07-02 | — | — | US | disclosed |
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2019-03-14 | — | — | US | disclosed |
| EP-0962457-B1 | Piperidones as tachykinin antagonists | PFIZER LTD (GB) | 2003-08-06 | — | — | EP | disclosed |
| EP-0992493-A1 | Substituted benzoylpiperidine derivatives and their use as Neurokinin antagonists | PFIZER INC. (US) | 2000-04-12 | — | — | EP | disclosed |
| EP-0962457-A1 | Piperidones as tachykinin antagonists | Pfizer Limited (GB) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190077790-A1 | 4-CYANO-BENZYL CARBAMIMIDOYLCARBAMATE DERIVATIVES AND THEIR USE AS AOC3 INHIBITORS | AOC3, AOC2, CBR3 | TP53 2034/4885NPSR1 3897/4885TSHR 4227/4885 |
| US-10336729-B2 | 4-cyano-benzyl carbamimidoylcarbamate derivatives and their use as AOC3 inhibitors | AOC3, AOC2, CBR3 | TP53 2034/4885NPSR1 3897/4885TSHR 4227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.